An alkylating agent used to treat many cancers.
« Back to Glossary IndexNews
Cisplatin
Related News
The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.
The 36th Annual Fanconi Anemia (FA) Scientific Symposium and Adult Retreat took place in Charlotte, North Carolina in September 2024, and brought together researchers, clinicians, advocates, individuals with FA and community members from across the globe. This year’s theme, “It Takes...
At the Fanconi Cancer Foundation (FCF), we understand the critical importance of addressing mental health alongside physical health for individuals with Fanconi anemia (FA) and their family caregivers. Recent research on the mental health challenges faced by adults with FA...